Answers are grounded in this paper and cite their sources.
Pharmaceuticals are the backbone of modern medicine, improving quality of life and extending life expectancy worldwide. However, growing concern surrounds their environmental impact, both during manufacturing and following consumption, with more than 4,000 unique active pharmaceutical ingredients currently listed in DrugBank. While the EU has established several frameworks and directives to support the removal and monitoring of micropollutants including pharmaceuticals, no harmonized approach currently exists for evaluating environmental risk beyond individual-substance assessments. To address this challenge, we propose a cumulative risk-calculation approach based on log transformation of risk-quotient (RQ) aggregation, termed the Cumulative Component Risk Index. Unlike the simple sum of RQs, which increases linearly and can overestimate risk when many substances are present at low levels, the CCRI provides a scaled, standardised estimate of mixture risk that remains comparable across different sites and seasons. To test the robustness and practical relevance of this approach, we analyse a case study using measured concentrations of ten pharmaceuticals in Latvian surface waters, sampled upstream and downstream of wastewater treatment plants across four seasons. The results of this study highlight the value of mixture-based evaluation approaches such as the CCRI, showing that a small number of high-impact pharmaceuticals can disproportionately shape environmental risk.
No takes yet. Share an insight, caveat, or question.
Putna-Nīmane et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: